comparemela.com

Latest Breaking News On - Myeloma program - Page 1 : comparemela.com

Cancer Researcher Thomas Martin Receives $4 6 million CIRM Grant

Talquetamab Dose Modifications May Lower AEs While Maintaining Efficacy in R/R Multiple Myeloma

Dr Chari on Findings From the MonumenTAL-1 Trial in Relapsed/Refractory Multiple Myeloma

Ajai Chari, MD, discusses the efficacy of treating patients with less frequent or lower intensity dosing of talquetamab in patients with relapsed/refractory multiple myeloma, as evaluated in the phase 1/2 MonumenTAL-1 study.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.